newsfilter
← Latest News
GlobeNewswire·

Aprea Therapeutics Announces Third Quarter 2026 Financial Results

Updated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026) in Barcelona on November 20, 2026APR-1051 Phase 1 clinical trial